PDGFRB and hepatocellular carcinoma: Sorafenib (Nexavar), a multi-kinase inhibitor including VEGFR2/3, PDGFRβ, and Flt-3, has been used to treat HCC patients and has a significant migration-inhibitory effect on HCC cells [26].